导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -3.65% | 3210/4764 |
| 近一周 | -1.98% | 3901/5455 |
| 近一月 | -7.05% | 3349/5409 |
| 近一季 | -9.32% | 2969/5227 |
| 近半年 | -4.60% | 2971/4921 |
| 近一年 | -1.05% | 2783/4391 |
| 近两年 | 41.05% | 1834/2946 |
| 近三年 | 23.79% | 1327/2246 |
| 成立以来 | 129.82% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.45% 3214/4961 |
12.21% 2204/5312 |
- - |
- - |
| 2025 | 20.81% 2086/4813 |
-0.15% 2082/3635 |
0.84% 2552/4076 |
20.17% 2017/4524 |
-0.16% 2390/4813 |
| 2024 | 15.14% 961/3463 |
2.94% 659/2808 |
-1.06% 910/3014 |
16.90% 1319/3129 |
-3.29% 2320/3463 |
| 2023 | -10.53% 1313/2656 |
4.64% 899/2280 |
-4.67% 1249/2385 |
-3.39% 914/2515 |
-7.15% 2073/2655 |
| 2022 | -19.64% 876/2207 |
-13.09% 697/1919 |
6.84% 594/2016 |
-14.43% 1094/2113 |
1.14% 1372/2208 |
| 2021 | -3.31% 898/1822 |
-1.85% 544/1255 |
3.37% 973/1330 |
-6.14% 902/1466 |
1.53% 888/1822 |
| 2020 | 39.35% 335/1250 |
-9.46% 677/1028 |
13.59% 607/1067 |
17.32% 107/1164 |
15.49% 204/1184 |
| 2019 | 39.27% 287/1092 |
24.07% 532/754 |
2.87% 67/804 |
1.90% 345/850 |
7.08% 489/918 |
| 2018 | -20.06% 187/834 |
- - |
- - |
- - |
-11.80% 353/691 |
| 2017 | 28.31% 78/714 |
- - |
- - |
- - |
- - |
| 2016 | -6.11% 191/605 |
- - |
- - |
- - |
- - |
| 2015 | -2.72% 269/575 |
- - |
- - |
- - |
- - |
| 2014 | 57.28% 45/237 |
- - |
- - |
- - |
- - |
| 2013 | -13.52% 169/186 |
- - |
- - |
- - |
- - |
| 2012 | 10.63% 38/140 |
- - |
- - |
- - |
- - |
| 2011 | -20.15% 39/102 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 国联安中证A100指数(LOF) VS. 长安沪深300非周期A(740101) |